DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)

South Korea flag South Korea · Delayed Price · Currency is KRW
17,450
-580 (-3.22%)
At close: Feb 6, 2026
10.44%
Market Cap780.69B +12.0%
Revenue (ttm)894.93B +13.4%
Net Income60.50B -1.4%
EPS1,358.99 -1.4%
Shares Out44.74M
PE Ratio12.84
Forward PE10.04
Dividend200.00 (1.15%)
Ex-Dividend DateDec 29, 2025
Volume243,347
Average Volume297,386
Open17,790
Previous Close18,030
Day's Range17,150 - 17,790
52-Week Range14,470 - 20,450
Beta0.25
RSI46.91
Earnings DateMar 11, 2026

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. produces and sells pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, cosmetics, and other products. Its pipeline includes DKF-MB601, used to treat Hepatitis B; DKF-MB501, to treat obesity; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, indicated for benign prostatic hyperplasia; DKF-447, to treat diabetes; DKB-123, used for wound healing, tissue repair; and DKM-428, used ... [Read more]

Sector Healthcare
Founded 1968
Employees 1,233
Stock Exchange KOSDAQ
Ticker Symbol 086450
Full Company Profile

Financial Performance

In 2024, DongKook Pharmaceutical's revenue was 812.17 billion, an increase of 11.10% compared to the previous year's 730.99 billion. Earnings were 60.77 billion, an increase of 29.92%.

Financial Statements